Hyarmendacil SA
Hyarmendacil reported total assets of €2.39m at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Aug 2026).
By total assets for 2025, Hyarmendacil ranks among the 200 largest of the 1,629 companies in its sector (NACE 5520) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Hyarmendacil shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +48 % Total assets -43 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Hyarmendacil's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 04 Dec 2024
- Year ended 31 Dec 2022filed on 04 Dec 2024
- Year ended 31 Dec 2021filed on 17 Oct 2022
Hyarmendacil's financial analysis
- Solvency78.2%sector median: 21.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Hyarmendacil
Hyarmendacil's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0444.108.857
- VAT number
- BE0444108857
- Peppol
- Registered · 0208:0444108857 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 11 Apr 1991
- Registered office
- 1730 Asse
- Latest accounts
- 2025 · filed on 30 Aug 2026
- Activity
- Homes and apartments for holiday (NACE 55203)
Hyarmendacil (SA) has been based in Asse since 1991, active in: homes and apartments for holiday. For 2025, it reports a net profit of €1.35m and equity of €1.87m; its revenue is not published. Its solvency stands at 78.2%, above the median of its sector (21.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Hyarmendacil
Companies in the same business, of comparable size and area, outside its group.
- Moulard Immo Cutting, shaping and finishing of stone Ath · balance sheet €2.39m
- EFGE Manufacture of basic pharmaceutical products Genk · balance sheet €2.39m
- Fidepark Antwerp · balance sheet €2.39m
- Immo FSM Wavre · balance sheet €2.32m
- LED life Aalst · balance sheet €2.39m
- Cherpi Family Holding Brussels · balance sheet €2.39m
- A.L.G. Genk Noord Wholesale of machine tools Genk · balance sheet €2.39m
- Immo Jeneffe Buying and selling of own real estate Donceel · balance sheet €2.39m
Frequently asked questions about Hyarmendacil
What is the revenue of Hyarmendacil?
Hyarmendacil files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Hyarmendacil?
In Belgium, the VAT number is the company number prefixed with BE: BE0444108857 for Hyarmendacil, if the company is VAT-registered. Its company number (CBE) is 0444.108.857.
Where is the registered office of Hyarmendacil?
According to the CBE register, the registered office of Hyarmendacil is in 1730 Asse.
What is the equity of Hyarmendacil?
At the close of the 2025 financial year, the equity of Hyarmendacil amounts to 1,867,470 €, a solvency of 78.2% of total assets.
Who manages Hyarmendacil?
The register lists 2 active mandates at Hyarmendacil. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Hyarmendacil within its sector?
By total assets for 2025, Hyarmendacil ranks among the 200 largest of the 1,629 companies in its sector (NACE 5520) in Belgium that filed accounts for that financial year.
The full file of Hyarmendacil
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →